R&G PharmaStudies Co., Ltd.

¥56.01As of Sun 8 Nov 2026, 12:00 UTC
SZSE:301333Healthcare
Country China
PE (Fwd) •••
TSR 4Y CAGR 3.04%
Div yield 0.29%
ROE 6.06%
Biotechnology
Beta (5Y) 0.46
PE TTM 45.88
TSR TTM (18.09%)
Mkt cap ¥5.320B
ROIC 28.22%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥59
4.50%
(38.39%)
Hold 8|11|11|1|10
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.53
0.58
0.63
0.62
(5.55%)
3.84%
14.49%
14.89%
Revenue¥M
569.5
603.1
606.5
593.8
2.47%
9.80%
6.66%
2.57%
Peers (US$797.6M)
Cap (US$)
PE
807.2M
496.4x
796.2M
—
Capital
TTM
5Y
10Y
Leveragex
1.301
1.111
0.789
EBIT/Intx
6.234
0.100
0.099
Own earn%
8.85
(37.21)
(42.00)
Sh yield%
39.33
30.50
32.26
Owners
Insiders/Inst%
3.91
22.55
Short interest%
3.80
SBC / revenue%
1.91
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
11–16
$1 testx
—
Incr. ROIC%
3